Current Status of Poly(ADP-ribose)‎ Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer

Abstract EN

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer that is clinically defined as lacking estrogen and progesterone receptors, as well as being ERBB2 (HER-2) negative.

Without specific therapeutic targets, TNBC carries a worse prognosis than other types of breast cancer in the absence of therapy.

Research has now further differentiated breast cancer into subtypes based on genetic expression patterns.

One of these subtypes, basal-like, frequently overlaps with the clinical picture of TNBC.

Additionally, both TNBC and basal-like breast cancer link to BRCA mutations.

Recent pharmaceutical advances have created a class of drugs, poly(ADP-ribose) polymerase (PARP) inhibitors, which are showing potential to effectively treat these patients.

The aim of this paper is to summarize the basis behind PARP inhibitors and update the current status of their development in clinical trials for the treatment of TNBC.